Clinical evaluation of Asparagine Synthetase (ASNS) Level in Leukemia/ Lymphoma Cells by Monoclonal Antibodies

Clinical evaluation of Asparagine Synthetase (ASNS) Level in Leukemia/ Lymphoma Cells by Monoclonal Antibodies - ASNS in Leukemia/Lymphoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000012119

Enrollment

Registered

2013-11-01

Start date

2012-07-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia/Lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with leukemia, multiple myeloma or malignant lymphoma who are refractory to/relapsed after one or more prior chemotherapies 2)Patients whose malignant cells are collected in bone marrow blood, or peripheral blood. 3) Patients with ECOG PS 0-1 4)Patients with adequate liver function: AST <2.5x ULN, ALT <2.5x ULN, T-Bil <2x ULN (except for disease activity) 5)Patients with adequate renal function: GFR >50 ml/min 6)Patients with adequate pulmonary function: %VC >80%, FEV1.0/FVC >70% 7)Patients with adequate cardiac function: EF >50% (assessed on cardiac ultrasonography)

Exclusion criteria

Exclusion criteria: 1) Patients with concomitant active cancer 2) Patients with active viral hepatitis or HBs-Ag positive 3) Patients with known CNS involvement of the lymphoma 4) Patients with previous serious allergy to any of the drugs given 5) Patients with abnormalities in cardiac function or clinically significant heart disease such as acute myocardial infarction or unstable angina within 6 months prior to the start of study treatment, heart failure NYHA class III or IV, uncontrolled hypertension or poor compliance of antihypertensive treatment, uncontrolled arrhythmias 6) Patients with serious or uncontrolled medical condition such as uncontrolled diabetes, uncontrolled active infection, significant cerebrovascular disease or poorly controlled psychiatric disease 7) Patients unable to give written informed consent 8) Others: Inappropriate patients determined by a principal investigator or sub-investigators

Design outcomes

Primary

Measure	Time frame
Evaluation of the effectiveness of flow cytometric estimation of ASNS Level in Leukemia/ Lymphoma or Suspension Cells by this Monoclonal Antibody.	—

Secondary

Measure	Time frame
To make sure that leukemia cells with low ASNS expression are sensitive to L-asparaginase in vitro MTT/WST-1 assay.	—

Countries

Japan,North America,Europe

Contacts

Public ContactToshiyuki Kitoh

Aichi Medical University Hospital Pediatrics

tkitoh@aichi-med-u.ac.jp0561-62-3311

Outcome results